Market News

Swiss Government to Purchase Additional Moderna Booster Vaccines

Moderna Inc. (NASDAQ: MRNA), one of the leading Biotech Stocks, has disclosed that the Swiss Federal Government has exercised its option to purchase an additional seven million doses of the company’s booster vaccine. The vaccines will be delivered in the second half of 2022.  

The Swiss government previously agreed to buy seven million doses of the booster vaccine for delivery in 2022, and these additional doses bring Switzerland’s total order thus far to 27.5 million doses.

Notably, Swissmedic has approved SPIKEVAX (elasomeran mRNA vaccine) for active immunization to prevent COVID-19 in people aged 12 years and older. 

CEO Comments 

The CEO of Moderna, Stephane Bancel, said, “We appreciate the collaboration with the Swiss Federal Government, and their continued support demonstrated by their increased supply agreement. We are encouraged by the initial data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels against the Omicron variant 37-fold higher than pre-boost levels. We will continue to make as many updates to our COVID-19 vaccine as necessary to control the pandemic.” 

Wall Street’s Take 

Recently, Goldman Sachs analyst Salveen Richter reiterated a Buy rating and a price target of $395 (60% upside potential) on Moderna. 

Overall, the stock has a Hold consensus rating based on 6 Buys, 6 Holds, and 3 Sells. The average Moderna price target of $311.83 implies 26.31% upside potential from current levels. Shares have gained 5.3% over the past six months. 

Risk Analysis 

According to the new TipRanks Risk Factors tool, Moderna stock is at risk mainly from three factors: Tech and Innovation, Finance and Corporate, and Legal and Regulatory, which contribute 29%, 22%, and 19%, respectively, to the total 98 risks identified for the stock.

Related News: 
HSBC Inks $425M Deal to Snap up L&T Investment Management 
Novavax & SK bioscience Announce Expansion of Collaboration Agreements 
Biogen & Eisai Receive FDA Fast Track Designation for Lecanemab

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More